We found the combination of the components with RT and anti-CTLA-4 conferred inferior anti-tumor efficacy, with no mice rendered disease-free at day 60 post-treatment (Supplementary Fig. 30b, c). This evidence concerns the gene CTLA4 and neoplasm.